Ithas been estimated that almost half a million women are alive today because of the useof tamoxifen in the treatment of ER+ breast cancer (5) and although tamoxifen has been the mainstay for the treatmentof ER+ disease for numerous years, many women develop endocrine resistanceand tamoxifen subsequently fails. Here, ESR1 is linked to breast carcinoma.